Skip to content

A prospective, randomized controled clinical study of celecoxib in combination with chemotherapy in patients with advanced gastric cancer

A prospective, randomized controled clinical study of celecoxib in patients with gastric cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10001158
Enrollment
Unknown
Registered
2010-12-27
Start date
2011-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

contrul group:FP regiem chemtherapy
experiment group:Celecoxib+FP regiem chemtherapy

Sponsors

The First Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Advanced gastric cancer confirmed by pathology, losing chance of radical surgery, or recurrence after surgery, no chemotherapy previously; 2. ECOG PS 0-2, Expected survival>12 weeks; 3. With normal function of vital organs: blood routine test: ANC>=1.5*10^9/l, PLT>=100*10^9/l, HB>=9g/l, liver function: TBIL <1.5normal limit, ALT/AST<2.5 normal limit for no liver metastasis, <5 normal limit for liver metastasis, renal function: Cr<1.25 normal limit, and normal ECG; 4. Aged from 18 to 65 years old; 5. Having mesurable lesions for RECIST criteria; 6. Understand contents of the study and sign informed consent forms.

Exclusion criteria

Exclusion criteria: 1. With severe allergic history, uncontrolled diabetes, hypertension and digestive ulcer; 2. With symptomatic brain metastasis; 3. With uncontrolled psychopathy; 4. Pregnant or breast-feeding women; 5. Using NSAID within 30 days of the study; 6. With other situation unsuitable for enrollment

Design outcomes

Primary

MeasureTime frame
Progression free survival;

Secondary

MeasureTime frame
Overall survival;Quality of Life;Response rate;Disease control rate;

Countries

China

Contacts

Public ContactYongning ZHOU
yongningzhou@sina.com+86 931-8625200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026